IDYA
Price
$33.14
Change
-$0.57 (-1.69%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
2.9B
132 days until earnings call
Intraday BUY SELL Signals
MREO
Price
$1.80
Change
-$0.02 (-1.10%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
288.03M
133 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

IDYA vs MREO

Header iconIDYA vs MREO Comparison
Open Charts IDYA vs MREOBanner chart's image
IDEAYA Biosciences
Price$33.14
Change-$0.57 (-1.69%)
Volume$9.83K
Capitalization2.9B
Mereo BioPharma Group
Price$1.80
Change-$0.02 (-1.10%)
Volume$22.38K
Capitalization288.03M
IDYA vs MREO Comparison Chart in %
IDYA
Daily Signal:
Gain/Loss:
MREO
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
IDYA vs. MREO commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a Hold and MREO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (IDYA: $33.70 vs. MREO: $1.83)
Brand notoriety: IDYA and MREO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IDYA: 62% vs. MREO: 96%
Market capitalization -- IDYA: $2.9B vs. MREO: $288.03M
IDYA [@Biotechnology] is valued at $2.9B. MREO’s [@Biotechnology] market capitalization is $288.03M. The market cap for tickers in the [@Biotechnology] industry ranges from $106.82B to $0. The average market capitalization across the [@Biotechnology] industry is $2.15B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IDYA’s FA Score shows that 1 FA rating(s) are green whileMREO’s FA Score has 1 green FA rating(s).

  • IDYA’s FA Score: 1 green, 4 red.
  • MREO’s FA Score: 1 green, 4 red.
According to our system of comparison, IDYA is a better buy in the long-term than MREO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IDYA’s TA Score shows that 4 TA indicator(s) are bullish while MREO’s TA Score has 3 bullish TA indicator(s).

  • IDYA’s TA Score: 4 bullish, 4 bearish.
  • MREO’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, IDYA is a better buy in the short-term than MREO.

Price Growth

IDYA (@Biotechnology) experienced а +5.28% price change this week, while MREO (@Biotechnology) price change was -2.41% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.17%. For the same industry, the average monthly price growth was -5.68%, and the average quarterly price growth was +64.91%.

Reported Earning Dates

IDYA is expected to report earnings on Mar 31, 2026.

MREO is expected to report earnings on Apr 01, 2026.

Industries' Descriptions

@Biotechnology (-2.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IDYA($2.9B) has a higher market cap than MREO($288M). IDYA YTD gains are higher at: 31.128 vs. MREO (-47.857). MREO has higher annual earnings (EBITDA): -47.49M vs. IDYA (-380.2M). IDYA has more cash in the bank: 670M vs. MREO (56.1M). MREO has less debt than IDYA: MREO (601K) vs IDYA (26.6M). IDYA has higher revenues than MREO: IDYA (7M) vs MREO (500K).
IDYAMREOIDYA / MREO
Capitalization2.9B288M1,008%
EBITDA-380.2M-47.49M801%
Gain YTD31.128-47.857-65%
P/E RatioN/AN/A-
Revenue7M500K1,400%
Total Cash670M56.1M1,194%
Total Debt26.6M601K4,426%
FUNDAMENTALS RATINGS
IDYA vs MREO: Fundamental Ratings
IDYA
MREO
OUTLOOK RATING
1..100
1774
VALUATION
overvalued / fair valued / undervalued
1..100
26
Undervalued
73
Overvalued
PROFIT vs RISK RATING
1..100
60100
SMR RATING
1..100
9597
PRICE GROWTH RATING
1..100
3864
P/E GROWTH RATING
1..100
1001
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IDYA's Valuation (26) in the null industry is somewhat better than the same rating for MREO (73). This means that IDYA’s stock grew somewhat faster than MREO’s over the last 12 months.

IDYA's Profit vs Risk Rating (60) in the null industry is somewhat better than the same rating for MREO (100). This means that IDYA’s stock grew somewhat faster than MREO’s over the last 12 months.

IDYA's SMR Rating (95) in the null industry is in the same range as MREO (97). This means that IDYA’s stock grew similarly to MREO’s over the last 12 months.

IDYA's Price Growth Rating (38) in the null industry is in the same range as MREO (64). This means that IDYA’s stock grew similarly to MREO’s over the last 12 months.

MREO's P/E Growth Rating (1) in the null industry is significantly better than the same rating for IDYA (100). This means that MREO’s stock grew significantly faster than IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IDYAMREO
RSI
ODDS (%)
Bearish Trend 2 days ago
64%
Bearish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
67%
Bullish Trend 2 days ago
85%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
88%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend about 1 month ago
81%
Declines
ODDS (%)
Bearish Trend 7 days ago
76%
Bearish Trend 7 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
73%
Bearish Trend 2 days ago
82%
Aroon
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
IDYA
Daily Signal:
Gain/Loss:
MREO
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ATLPF15.800.05
+0.32%
Atlas Copco AB
ASXFF38.50N/A
N/A
ASX, Ltd.
BEOB101.50N/A
N/A
BEO Bancorp
ASGTF35.20-0.54
-1.51%
Altus Group Ltd
LTUM0.12-0.01
-4.98%
Lithium Corporation.